A new cost analysis highlights that manufacturing natural killer cell therapies using induced pluripotent stem cells (iPSCs) can reduce cost of goods sold dramatically versus traditional autologous or allogeneic approaches. The analysis reports that iPSC-based manufacturing could cut per-treatment costs by as much as 95%, potentially bringing costs toward the low-thousands per dose. The assessment argues that decoupling production from individual patients allows standardized batches, reduced labor intensity, and a simpler operating model for scaling. It frames a commercial manufacturing structure built around universal master cell banks feeding working banks that generate intermediate cells for downstream differentiation. The report’s pricing ranges—contrasting iPSC-derived doses at roughly $5,000 versus autologous and allogeneic benchmarks—aim to clarify how economics may influence payer adoption and long-term supply stability for next-generation immune cell products.